BNP Paribas Financial Markets Lowers Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

BNP Paribas Financial Markets reduced its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 25.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,789 shares of the company's stock after selling 2,644 shares during the period. BNP Paribas Financial Markets' holdings in Krystal Biotech were worth $1,220,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of KRYS. Covestor Ltd boosted its holdings in shares of Krystal Biotech by 972.7% during the fourth quarter. Covestor Ltd now owns 708 shares of the company's stock worth $111,000 after purchasing an additional 642 shares during the period. Avanza Fonder AB purchased a new stake in Krystal Biotech in the fourth quarter worth about $119,000. KBC Group NV lifted its holdings in Krystal Biotech by 46.3% in the fourth quarter. KBC Group NV now owns 939 shares of the company's stock worth $147,000 after buying an additional 297 shares during the period. Blue Trust Inc. lifted its holdings in Krystal Biotech by 74.4% in the fourth quarter. Blue Trust Inc. now owns 1,015 shares of the company's stock worth $159,000 after buying an additional 433 shares during the period. Finally, US Bancorp DE lifted its holdings in Krystal Biotech by 8.7% in the fourth quarter. US Bancorp DE now owns 1,027 shares of the company's stock worth $161,000 after buying an additional 82 shares during the period. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have commented on KRYS. Guggenheim lowered their price objective on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Chardan Capital restated a "buy" rating and issued a $219.00 price objective on shares of Krystal Biotech in a report on Wednesday, May 7th. Jefferies Financial Group began coverage on shares of Krystal Biotech in a report on Wednesday, March 5th. They issued a "buy" rating and a $245.00 price objective for the company. HC Wainwright restated a "buy" rating and issued a $240.00 price objective on shares of Krystal Biotech in a report on Tuesday, May 6th. Finally, Citigroup decreased their target price on shares of Krystal Biotech from $215.00 to $155.00 and set a "neutral" rating for the company in a research note on Friday, May 16th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $211.13.

Insiders Place Their Bets

In other news, CAO Kathryn Romano sold 750 shares of Krystal Biotech stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total transaction of $131,415.00. Following the transaction, the chief accounting officer now owns 12,604 shares in the company, valued at $2,208,472.88. This trade represents a 5.62% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the transaction, the insider now owns 1,463,711 shares in the company, valued at $260,233,178.69. This represents a 1.68% decrease in their position. The disclosure for this sale can be found here. 13.70% of the stock is currently owned by insiders.

Krystal Biotech Stock Performance

Shares of KRYS traded down $0.24 on Friday, hitting $125.05. 298,645 shares of the stock traded hands, compared to its average volume of 308,069. The company has a market capitalization of $3.61 billion, a PE ratio of 41.82 and a beta of 0.79. The business has a 50 day simple moving average of $161.34 and a 200 day simple moving average of $166.79. Krystal Biotech, Inc. has a one year low of $122.80 and a one year high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported $1.20 earnings per share for the quarter, missing the consensus estimate of $1.38 by ($0.18). The firm had revenue of $88.18 million for the quarter, compared to the consensus estimate of $98.66 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. On average, equities analysts expect that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).